Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...
Over the last 5 years, the share price of Lodha Developers has gained 35.70% CAGR. Over the past year, the corresponding return has been -18.51%. Lodha Developers’s current P/E of 31.97x helps give ...
A largely undeveloped site in Fremont that's across the street from a PG&E substation has been bought.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback